Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies
| Autor: | N. Schweitzer, A. Vogel |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cisplatin
Oncology Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Gastroenterology Combination chemotherapy Disease Systemic therapy Gemcitabine Targeted therapy Cholangiocarcinoma Clinical trial Bile Ducts Intrahepatic Bile Duct Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Molecular Targeted Therapy business medicine.drug |
| Zdroj: | Best Practice & Research Clinical Gastroenterology. 29:345-353 |
| ISSN: | 1521-6918 |
| DOI: | 10.1016/j.bpg.2015.01.002 |
| Popis: | Cholangiocarcinomas (CCA) are rare tumors of the liver with poor prognosis. The standard of care in patients with unresectable tumors or metastatic disease is combination chemotherapy (CT) with gemcitabine and cisplatin. Targeted therapies inhibiting EGFR, VEGF, MEK and others are broadly tested in CCA but to date, the existing data from randomized and nonrandomized trials do not justify the application of small molecules outside of clinical trials. In clinical practice, many patients receive second-line CT after failure of gemcitabine/cisplatin, although there is so far no evidence to support second-line CT. This review summarizes current chemotherapy protocols and ongoing studies, including conventional chemotherapy and targeted therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect